Financhill
Buy
52

JAZZ Quote, Financials, Valuation and Earnings

Last price:
$121.64
Seasonality move :
5.12%
Day range:
$122.87 - $125.59
52-week range:
$99.06 - $134.17
Dividend yield:
0%
P/E ratio:
17.43x
P/S ratio:
2.05x
P/B ratio:
1.79x
Volume:
429.7K
Avg. volume:
586.7K
1-year change:
-2.5%
Market cap:
$7.5B
Revenue:
$3.8B
EPS (TTM):
$7.10

Analysts' Opinion

  • Consensus Rating
    Jazz Pharmaceuticals PLC has received a consensus rating of Buy. The company's average rating is a Buy based on 8 Buy ratings, 3 Hold ratings, and 0 Sell ratings.
  • Price Target Upside
    According to analysts' consensus price target of $181.05, Jazz Pharmaceuticals PLC has an estimated upside of 46.29% from its current price of $123.76.
  • Price Target Downside
    According to analysts, the lowest downside price target is $128.00 representing 100% downside risk from its current price of $123.76.

Fair Value

  • According to the consensus of 11 analysts, Jazz Pharmaceuticals PLC has 46.29% upside to fair value with a price target of $181.05 per share.

JAZZ vs. S&P 500

  • Over the past 5 trading days, Jazz Pharmaceuticals PLC has overperformed the S&P 500 by 1.77% suggesting its relative strength compared to the major market average is strong at this time.

Share Buyback

  • Jazz Pharmaceuticals PLC does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.

Revenue Growth

  • Jazz Pharmaceuticals PLC has grown year-over-year revenues for 64 quarters straight. In the most recent quarter Jazz Pharmaceuticals PLC reported revenues of $1.1B.

Earnings Growth

  • Jazz Pharmaceuticals PLC has grown year-over-year earnings for 2 quarters straight. In the most recent quarter Jazz Pharmaceuticals PLC reported earnings per share of $3.42.
Enterprise value:
11B
EV / Invested capital:
--
Price / LTM sales:
2.05x
EV / EBIT:
16.74x
EV / Revenue:
2.75x
PEG ratio (5yr expected):
0.02x
EV / Free cash flow:
9.96x
Price / Operating cash flow:
7.44x
Enterprise value / EBITDA:
8.40x
Gross Profit (TTM):
$3.6B
Return On Assets:
4.03%
Net Income Margin (TTM):
11.6%
Return On Equity:
12.28%
Return On Invested Capital:
4.84%
Operating Margin:
24.67%
Trailing 12 Months Fiscal Quarters
Period Ending 2022-09-30 2023-09-30 2024-09-30 2023-09-30 2024-09-30
Income Statement
Revenue $3.6B $3.8B $4B $972.1M $1.1B
Gross Profit $3.1B $3.3B $3.6B $870M $943.4M
Operating Income $450M $568.7M $676.4M $172.4M $260.2M
EBITDA $874.5M $813.9M $1.3B $333.6M $424.7M
Diluted EPS -$0.30 $0.88 $7.10 $2.14 $3.42
Period Ending 2020-09-30 2021-09-30 2022-09-30 2023-09-30 2024-09-30
Balance Sheet
Current Assets $2.6B $2.6B $2.6B $3.2B $4.4B
Total Assets $6.3B $12.5B $10.4B $11.2B $12.3B
Current Liabilities $642.1M $735.1M $813M $1.6B $1B
Total Liabilities $2.9B $8.5B $7.6B $7.7B $8.1B
Total Equity $3.4B $3.9B $2.7B $3.5B $4.2B
Total Debt $2.1B $6.3B $5.7B $5.7B $6.1B
Trailing 12 Months Fiscal Quarters
Period Ending 2022-09-30 2023-09-30 2024-09-30 2023-09-30 2024-09-30
Cash Flow Statement
Cash Flow Operations $1.1B $1.3B $1.2B $307.2M $398.7M
Cash From Investing -$131.9M -$589.2M -$213.1M -$174.3M $214.1M
Cash From Financing -$795.7M -$185.4M -$71.5M -$78.5M $246.4M
Free Cash Flow $984M $867.4M $1.1B $302.9M $388M
JAZZ
Sector
Market Cap
$7.5B
$48.6M
Price % of 52-Week High
92.24%
47.39%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.74%
1-Year Price Total Return
-2.5%
-33.25%
Beta (5-Year)
0.563
0.754
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Technicals

8-day SMA
Sell
Level $123.91
200-day SMA
Buy
Level $112.95
Bollinger Bands (100)
Buy
Level 108.94 - 121.88
Chaikin Money Flow
Buy
Level 13.6M
20-day SMA
Buy
Level $123.05
Relative Strength Index (RSI14)
Buy
Level 53.92
ADX Line
Sell
Level 20.67
Williams %R
Neutral
Level -41.9233
50-day SMA
Buy
Level $120.06
MACD (12, 26)
Buy
Level 0.95
25-day Aroon Oscillator
Buy
Level 4
On Balance Volume
Neutral
Level 197.6M

Financial Scores

Sell
Altman Z-Score (Annual)
Level (1.4147)
Sell
CA Score (Annual)
Level (-0.9783)
Buy
Beneish M-Score (Annual)
Level (-2.7113)
Buy
Momentum Score
Level (3)
Buy
Ohlson Score
Level (-0.5992)
Buy
Piotroski F Score (Annual)
Level (7)
Buy
Quality Ratio Score
Level (5)
Buy
Fundamental Score
Level (6)

Revenue Forecast

Earnings per Share Forecast

Company Profile

Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.

Stock Forecast FAQ

In the current month, JAZZ has received 8 Buy ratings 3 Hold ratings, and 0 Sell ratings. The JAZZ average analyst price target in the past 3 months is $181.05.

  • Where Will Jazz Pharmaceuticals PLC Stock Be In 1 Year?

    According to analysts, the consensus estimate is that Jazz Pharmaceuticals PLC share price will rise to $181.05 per share over the next 12 months.

  • What Do Analysts Say About Jazz Pharmaceuticals PLC?

    Analysts are divided on their view about Jazz Pharmaceuticals PLC share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Jazz Pharmaceuticals PLC is a Sell and believe this share price will drop from its current level to $128.00.

  • What Is Jazz Pharmaceuticals PLC's Price Target?

    The price target for Jazz Pharmaceuticals PLC over the next 1-year time period is forecast to be $181.05 according to 11 Wall Street analysts, 8 of them rate the stock a Buy, 0 rate the stock a Sell, and 3 analysts rate the stock a Hold.

  • Is JAZZ A Buy, Sell Or Hold?

    According to Wall Street analysts, the consensus rating for Jazz Pharmaceuticals PLC is a Buy. 8 of 11 analysts rate the stock a Buy at this time.

  • How Can I Buy Shares Of JAZZ?

    You can purchase shares of Jazz Pharmaceuticals PLC via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Jazz Pharmaceuticals PLC shares.

  • What Is The Jazz Pharmaceuticals PLC Share Price Today?

    Jazz Pharmaceuticals PLC was last trading at $121.64 per share. This represents the most recent stock quote for Jazz Pharmaceuticals PLC. Yesterday, Jazz Pharmaceuticals PLC closed at $123.76 per share.

  • How To Buy Jazz Pharmaceuticals PLC Stock Online?

    In order to purchase Jazz Pharmaceuticals PLC stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Why Did Carlos Slim Buy PBF Energy?
Why Did Carlos Slim Buy PBF Energy?

Carlos Slim made a splash in a surprising sector last…

Is Booking Holdings Stock Undervalued?
Is Booking Holdings Stock Undervalued?

There is a lot of humdrum in the market about…

Broadcom vs American Express: Which Is Best?
Broadcom vs American Express: Which Is Best?

Chip giant Broadcom Inc. (NASDAQ:AVGO) and card company American Express…

Stock Ideas

Sell
48
Is AAPL Stock a Buy?

Market Cap: $3.7T
P/E Ratio: 40x

Buy
51
Is NVDA Stock a Buy?

Market Cap: $3.4T
P/E Ratio: 116x

Sell
43
Is MSFT Stock a Buy?

Market Cap: $3.1T
P/E Ratio: 35x

Alerts

Sell
47
DRUG alert for Jan 3

Bright Minds Biosciences [DRUG] is down 4.28% over the past day.

Buy
88
BMA alert for Jan 3

Banco Macro SA [BMA] is up 0.88% over the past day.

Sell
50
AGFY alert for Jan 3

Agrify [AGFY] is down 5.86% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock